Canada markets closed

Tivic Health Systems, Inc. (TIVC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5051-0.0849 (-14.39%)
At close: 04:00PM EDT
0.5076 +0.00 (+0.49%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.5900
Open0.5311
Bid0.3778 x 200
Ask0.6501 x 200
Day's Range0.4966 - 0.5489
52 Week Range0.4960 - 21.8000
Volume1,175,247
Avg. Volume655,583
Market Cap744,310
Beta (5Y Monthly)2.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Tivic Health Announces Pricing of $4.0 Million Public Offering

    SAN FRANCISCO, May 09, 2024--Tivic Health® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its public offering of an aggregate of 4,710,000 shares of its common stock, Series A warrants to purchase up to 4,710,000 shares of common stock and Series B warrants to purchase up to 7,065,000 shares of common stock, at a public offering price of $0.85 per share and accompanying warrants. The Series A wa

  • Business Wire

    Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (VNS); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

    SAN FRANCISCO, May 08, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today the final results of their pilot research study with The Feinstein Institutes for Medical Research at Northwell Health. Through this collaboration, Tivic Health has confirmed the effectiveness of its patent-pending non-invasive cervical vagus nerve stimulation (ncVNS) approach, which induces responses in the autono

  • Business Wire

    Tivic Reports Fiscal Year 2023 Financial Results

    SAN FRANCISCO, March 25, 2024--Tivic Health® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2023.